Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Sugammadex in Obese Patients
NCT04131218Phase 4Unknown
- Sponsor
- General Hospital of Southern Theater Command of the People's Liberation Army
- Start
- Jul 2019
- Primary completion
- Jul 2020
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by General Hospital of Southern Theater Command of the People's Liberation Army. Primary endpoints: Plasma Concentration of Sugammadex at 8 hours and Recovery Time and TOF ratio. Status: unknown.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT04131218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04131218.